Bank Of America Corp Crinetics Pharmaceuticals, Inc. Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 357,142 shares of CRNX stock, worth $16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

357,142

Previous 344,413 3.7%

Holding current value

$16 Million

Previous $12.3 Million 36.42%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $442,460 - $595,844	12,729 Added 3.7%	357,142 $16.7 Million
Q4 2023 Feb 14, 2024	BUY	$25.62 - $37.07 $5.74 Million - $8.31 Million	224,039 Added 186.12%	344,413 $12.3 Million
Q2 2023 Aug 14, 2023	SELL	$15.73 - $23.6 $882,437 - $1.32 Million	-56,099 Reduced 31.79%	120,374 $2.17 Million
Q1 2023 May 12, 2023	BUY	$15.31 - $21.1 $802,335 - $1.11 Million	52,406 Added 42.24%	176,473 $2.83 Million
Q4 2022 Feb 10, 2023	BUY	$15.49 - $19.05 $1 Million - $1.23 Million	64,610 Added 108.67%	124,067 $2.27 Million

Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $93,646 - $115,675	5,171 Added 9.53%	59,457 $1.17 Million
Q2 2022 Aug 12, 2022	SELL	$16.49 - $27.64 $719,755 - $1.21 Million	-43,648 Reduced 44.57%	54,286 $1.01 Million
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $511,704 - $844,685	29,837 Added 43.82%	97,934 $2.15 Million
Q4 2021 Feb 08, 2022	BUY	$19.35 - $28.41 $1.09 Million - $1.6 Million	56,475 Added 485.93%	68,097 $1.94 Million
Q3 2021 Nov 15, 2021	SELL	$16.88 - $25.23 $25,100 - $37,517	-1,487 Reduced 11.34%	11,622 $245,000
Q2 2021 Sep 13, 2021	BUY	$15.9 - $21.15 $208,433 - $277,255	13,109 New	13,109 $247,000

Others Institutions Holding CRNX

# of Institutions

220

Shares Held

75.8M

Call Options Held

631K

Put Options Held

749K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.41B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Crinetics Pharmaceuticals, Inc. Transaction History